Meritage Portfolio Management Acquires 157 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Meritage Portfolio Management increased its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 12.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,446 shares of the biotechnology company’s stock after acquiring an additional 157 shares during the quarter. Meritage Portfolio Management’s holdings in United Therapeutics were worth $510,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of the business. Geode Capital Management LLC grew its holdings in United Therapeutics by 4.3% in the third quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company’s stock worth $391,459,000 after purchasing an additional 45,566 shares during the period. FMR LLC grew its stake in shares of United Therapeutics by 41.1% in the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after buying an additional 314,004 shares during the last quarter. Pacer Advisors Inc. grew its stake in shares of United Therapeutics by 5.5% in the 4th quarter. Pacer Advisors Inc. now owns 597,634 shares of the biotechnology company’s stock worth $210,869,000 after buying an additional 30,931 shares during the last quarter. Janus Henderson Group PLC increased its position in United Therapeutics by 12.3% during the 3rd quarter. Janus Henderson Group PLC now owns 460,419 shares of the biotechnology company’s stock valued at $164,978,000 after buying an additional 50,409 shares in the last quarter. Finally, Assetmark Inc. raised its stake in United Therapeutics by 56.9% during the third quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock valued at $150,492,000 after buying an additional 152,249 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

UTHR has been the topic of a number of recent research reports. HC Wainwright increased their target price on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. UBS Group increased their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Argus lifted their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. The Goldman Sachs Group increased their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. Finally, Oppenheimer raised their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average price target of $382.08.

Insider Buying and Selling at United Therapeutics

In other news, EVP Paul A. Mahon sold 7,700 shares of the business’s stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the completion of the sale, the executive vice president now owns 36,710 shares of the company’s stock, valued at $13,485,785.60. The trade was a 17.34 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Judy D. Olian sold 1,750 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $412.48, for a total value of $721,840.00. Following the completion of the transaction, the director now directly owns 5,655 shares in the company, valued at approximately $2,332,574.40. This represents a 23.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 128,838 shares of company stock valued at $47,960,356. 11.90% of the stock is owned by company insiders.

United Therapeutics Price Performance

NASDAQ UTHR opened at $354.18 on Thursday. The stock has a market capitalization of $15.81 billion, a price-to-earnings ratio of 15.55, a PEG ratio of 0.92 and a beta of 0.57. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $417.82. The business’s fifty day moving average price is $363.80 and its 200-day moving average price is $357.66.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.